Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toxicity test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,287 result(s) found for: Toxicity test. Displaying page 1 of 215.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-002635-28 Sponsor Protocol Number: 69081 Start Date*: 2019-10-14
    Sponsor Name:University Medical Center Utrecht
    Full Title: The effect of hyperbaric oxygen therapy on breast cancer patients with late radiation toxicity
    Medical condition: Late radiation toxicity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022938-85 Sponsor Protocol Number: AIO-LQ-0110 Start Date*: 2011-04-27
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer
    Medical condition: Panitumumab-mediated Skin toxicity in palliative treatment of Metastatic colorectal cancer with panitumumab
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004413-98 Sponsor Protocol Number: DERMIA Start Date*: 2018-03-27
    Sponsor Name:Fundación CRIS
    Full Title: “Phase II clinical trial of doxycycline 50 mg or 100 mg daily for the prevention of skin toxicity in patients with metastatic colorectal cancer treated with panitumumab and chemotherapy"
    Medical condition: Cutaneous toxicity in patients with metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10059516 Skin toxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003617-18 Sponsor Protocol Number: 1439A-028 Start Date*: 2016-01-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching from ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A ...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000985-31 Sponsor Protocol Number: RALAM-II Start Date*: 2017-10-04
    Sponsor Name:Fundació Clinic per a la Recerca Biomédica
    Full Title: Phase 3b, single arm, single site simplification study with dual therapy including 3TC (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected atients experiencing inco...
    Medical condition: Virologically suppressed Human Immunodeficiency Virus-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020168 10020445 Human immunodeficiency virus type I infection with constitutional disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004003-12 Sponsor Protocol Number: FluorouracilCapecitabine001 Start Date*: 2020-01-14
    Sponsor Name:Jessa Hospital
    Full Title: Implementation of pre-emptive geno- and phenotyping in 5-FU- or capecitabine-treated patients with the aim of reducing toxicity
    Medical condition: Gastro-intestinal cancers: stomach, pancreas, colon, rectum, anal tumors, esophagus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002258-60 Sponsor Protocol Number: UMCN-ONCO-201302 Start Date*: 2013-08-30
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002861-37 Sponsor Protocol Number: EURABEL-2 Start Date*: 2007-01-19
    Sponsor Name:Ziekenhuisapotheek Meppel-Hoogeveen
    Full Title: Evaluation of the oral uracil loading test as a sensitive, simple and cheap method to detect DPD deficiency.
    Medical condition: Extreme toxicity during of after chemotherapy with a 5-fluorouracil of capecitabine containing regimen for colorectal, breast or head and neck cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001224-21 Sponsor Protocol Number: MV18220 Start Date*: 2005-01-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV t...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    10020161
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001577-33 Sponsor Protocol Number: D24-DIPG Start Date*: 2016-11-03
    Sponsor Name:Clínica Universidad de Navarra
    Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.
    Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003859-61 Sponsor Protocol Number: PM0259CA232J1 Start Date*: 2015-07-28
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy
    Medical condition: Advanced Non Small Lung Cancer unfit for a platinium-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed) HU (Completed) CZ (Completed) DE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005357-21 Sponsor Protocol Number: L-9918 Start Date*: 2006-04-24
    Sponsor Name:ACROSS
    Full Title: Estudio aleatorizado fase III multicéntrico sobre la eficacia de las infusiones de calcio y magnesio en la prevención de la neurotoxicidad inducida por el tratamiento adyuvante del cáncer de colon
    Medical condition: COLON ADENOCARCINOMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001031-22 Sponsor Protocol Number: CCR2749 Start Date*: 2007-12-18
    Sponsor Name:Institute of Cancer Research
    Full Title: The Potentiation of Efficacy of Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC) by Inhibition of Akt Activation
    Medical condition: Non-small-cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004029-24 Sponsor Protocol Number: TOGA 0501 Start Date*: 2007-08-17
    Sponsor Name:Thoracale Oncologie Groep Antwerpen TOGA
    Full Title: Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lumg Cancer (NSCLC)
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001926-26 Sponsor Protocol Number: XERXES Start Date*: 2005-06-10
    Sponsor Name:University College London
    Full Title: XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery. A phase I/II dose escalation study of intr...
    Medical condition: Locally advanced rectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005088-25 Sponsor Protocol Number: 01234 Start Date*: 2006-11-15
    Sponsor Name:Leiden University Medical Center
    Full Title: Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases.
    Medical condition: Patients with isolated hepatic metastases of histologically confirmed colorectal adenocarcinoma and for the phase I study also isolated hepatic metastases of all other solid tumors.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000833-40 Sponsor Protocol Number: CCR4502 Start Date*: 2016-10-07
    Sponsor Name:The Institute of Cancer Research
    Full Title: Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of...
    Medical condition: Women with locally advanced/recurrent breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005116-28 Sponsor Protocol Number: 38495 Start Date*: 2012-09-10
    Sponsor Name:
    Full Title: A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial
    Medical condition: Metastatic prostate cancer/bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004576-22 Sponsor Protocol Number: IRI28 Start Date*: 2017-07-14
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018878-21 Sponsor Protocol Number: SSAT036 Start Date*: 2010-08-16
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to ral...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:25:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA